Filip Baert

19.0k total citations · 8 hit papers
137 papers, 11.0k citations indexed

About

Filip Baert is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, Filip Baert has authored 137 papers receiving a total of 11.0k indexed citations (citations by other indexed papers that have themselves been cited), including 116 papers in Genetics, 88 papers in Epidemiology and 40 papers in Surgery. Recurrent topics in Filip Baert's work include Inflammatory Bowel Disease (116 papers), Microscopic Colitis (75 papers) and Eosinophilic Esophagitis (20 papers). Filip Baert is often cited by papers focused on Inflammatory Bowel Disease (116 papers), Microscopic Colitis (75 papers) and Eosinophilic Esophagitis (20 papers). Filip Baert collaborates with scholars based in Belgium, Netherlands and United States. Filip Baert's co-authors include Gert Van Assche, Geert D’Haens, Séverine Vermeire, Paul Rutgeerts, Maja Noman, An Carbonez, Marc Peeters, P. Rutgeerts, Freddy Penninckx and Marc Ferrante and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Filip Baert

129 papers receiving 10.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

2003 1.6k citations Filip Baert, Maja Noman et al. profile →
Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD

2004 1.3k citations Geert D’Haens, Gert Van Assche et al. profile →
Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum

1998 668 citations Geert D’Haens, Karel Geboes et al. Gastroenterology profile →
Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's Disease

2009 648 citations Filip Baert, Gert Van Assche et al. Gastroenterology profile →
Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease

2012 628 citations Geert D’Haens, Marc Ferrante et al. Inflammatory Bowel Diseases profile →
Endoscopic and histological healing with infliximab anti–tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial

1999 585 citations Geert D’Haens, Sander van Deventer et al. Gastroenterology profile →
Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis

2019 212 citations Filip Baert, Silvio Danese et al. Gastroenterology profile →
Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies

2023 190 citations Séverine Vermeire, Filip Baert et al. profile →

Peers

Countries citing papers authored by Filip Baert

Since Specialization

Citations

This map shows the geographic impact of Filip Baert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Filip Baert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Filip Baert more than expected).

Fields of papers citing papers by Filip Baert

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Filip Baert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Filip Baert. The network helps show where Filip Baert may publish in the future.

Co-authorship network of co-authors of Filip Baert

This figure shows the co-authorship network connecting the top 25 collaborators of Filip Baert. A scholar is included among the top collaborators of Filip Baert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Filip Baert. Filip Baert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	DOP049 Vedolizumab is more effective at inducing histo-endoscopic healing in early Crohn’s Disease compared to late CD, with comparable healing rates regardless of disease location: data from the LOVE-CD trial 2025 ·Journal of Crohn s and Colitis ·(unknown), (unknown), Filip Baert, Peter Bossuyt, Mark Löwenberg, (unknown), Frank Hoentjen, Tamás Molnár, Geert D’Haens, Séverine Vermeire	0
2	P0949 Long term real-world effectiveness and safety of upadacitinib in patients with moderate to severe Crohn’s disease: A Belgian multi-centric refractory cohort 2025 ·Journal of Crohn s and Colitis ·(unknown), (unknown), Sophie Vieujean, (unknown), (unknown), (unknown), Filip Baert, Michaël Somers, Olivier Dewit, Patrick M. Bossuyt, (unknown), Tom Holvoet, Romy Ouziel, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Anneline Cremer	0
3	P845 Vedolizumab induces endoscopic healing uniformly irrespective of disease location: post-hoc analysis of the LOVE-CD trial 2024 ·Journal of Crohn s and Colitis ·Bart Hens, (unknown), Tamás Molnár, Filip Baert, (unknown), Séverine Vermeire, Mark Löwenberg, Geert D’Haens	3
4	Baseline Data and Measurement Instruments Reported in Observational Studies in Inflammatory Bowel Disease: Results from a Systematic Review 2024 ·Journal of Crohn s and Colitis ·(unknown), (unknown), Valérie Pittet, Peter Bossuyt, Jurij Hanžel, Mark Samaan, Monika Tripathi, Wladyslawa Czuber‐Dochan, Johan Burisch, S. Leone, (unknown), Filip Baert, Uri Kopylov, Susanna Jäghult, Michel Adamina, K Gecse, Naila Arebi	1
5	Development of a Core Outcome Set for Real-world Data in Inflammatory Bowel Disease: A European Crohn’s and Colitis Organisation [ECCO] Position Paper 2022 ·Journal of Crohn s and Colitis ·Jurij Hanžel, Peter Bossuyt, Valérie Pittet, Mark Samaan, Monika Tripathi, Wladyslawa Czuber‐Dochan, Johan Burisch, S. Leone, (unknown), Filip Baert, Uri Kopylov, Susanna Jäghult, Michel Adamina, Naila Arebi, K Gecse	9
6	A Narrative Systematic Review and Categorisation of Outcomes in Inflammatory Bowel Disease to Inform a Core Outcome Set for Real-world Evidence 2022 ·Journal of Crohn s and Colitis ·(unknown), (unknown), Peter Bossuyt, Valérie Pittet, Jurij Hanžel, Mark Samaan, Monika Tripathi, Wladyslawa Czuber‐Dochan, Johan Burisch, S. Leone, (unknown), Filip Baert, Uri Kopylov, Susanna Jäghult, Michel Adamina, K Gecse, Naila Arebi	7
7	Risk of Development of More-advanced Lesions in Patients With Inflammatory Bowel Diseases and Dysplasia 2019 ·Clinical Gastroenterology and Hepatology ·Anneline Cremer, Pieter Demetter, Martine De Vos, (unknown), Filip Baert, Tom G. Moreels, Elisabeth Macken, Édouard Louis, Liesbeth Ferdinande, (unknown), Franceska Dedeurwaerdere, (unknown), Ann Driessen, Gert De Hertogh, Séverine Vermeire, Denis Franchimont	29
8	Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn’s Disease 2019 ·Clinical Gastroenterology and Hepatology ·Erwin Dreesen, Filip Baert, David Laharie, Peter Bossuyt, Yoram Bouhnik, Anthony Buisson, Guy Lambrecht, Édouard Louis, Bas Oldenburg, Benjamin Pariente, Marieke Pierik, C. Janneke van der Woude, Geert D’Haens, Séverine Vermeire, Ann Gils	60
9	OTH-12 Efficacy and safety of vedolizumab subcutaneous formulation for ulcerative colitis: results of the visible trial 2019 ·WJ Sandborn, Filip Baert, Silvio Danese, (unknown), Geert D’Haens, Taku Kobayashi, (unknown), Jingjing Chen, Krisztina Kisfalvi, Séverine Vermeire	1
10	Belgian IBD research group (BIRD) position statement 2017 on the use of biosimilars in inflammatory bowel diseases (IBD). 2018 ·PubMed ·(unknown), Marc Ferrante, Édouard Louis, Martine De Vos, Olivier Dewit, (unknown), Tom G. Moreels, Claire Liefferinckx, Peter Bossuyt, Filip Baert, Jean‐François Rahier, Séverine Vermeire	3
11	Efficacy of switching to infliximab in patients with Crohn's disease with loss of response to adalimumab. 2018 ·PubMed ·Harald Peeters, Édouard Louis, Filip Baert, Olivier Dewit, J.-C. Coche, Marc Ferrante, Guy Lambrecht, (unknown), A. Van Gossum, Peter Bossuyt, Tom G. Moreels, Bert Vander Cruyssen, Ann Gils, Martine De Vos	7
12	Methotrexate in refractory Crohn's disease 2007 ·Inflammatory Bowel Diseases ·Lieven Vandeputte, Geert D’Haens, Filip Baert, (unknown)	3
13	The ideal management of Crohn's disease: Top down versus step up strategies, a randomized controlled trial 2006 ·Ghent University Academic Bibliography (Ghent University) ·DW Hommes, Filip Baert, Gert Van Assche, (unknown), Philippe Vergauwe, Hans A.R.E. Tuynman, Martine De Vos, SJ van Deventer, Larry Stitt, Paul Rutgeerts, (unknown), G. D’Haens	29
14	A randomized controlled trial evaluating the ideal medical management for Crohn's disease (CD): Top-down versus step-up strategies 2005 ·Ghent University Academic Bibliography (Ghent University) ·DW Hommes, Filip Baert, Gert Van Assche, Philip Caenepeel, Philippe Vergauwe, Hans A.R.E. Tuynman, Martine De Vos, SJ van Deventer, Larry Stitt, Paul Rutgeerts, Allan Donner, (unknown), Geert D’Haens	24
15	Randomized placebo controlled trial of pro- and prebiotics (synbiotics cocktail) for maintenance of infliximab induced remission of luminal Crohn's disease (CD) 2004 ·UCL Discovery (University College London) ·Paul Rutgeerts, Geert D’Haens, Filip Baert, Gert Van Assche, Isolde Aerden, Maja Noman, Séverine Vermeire, Stig Bengmark	11
16	Methotrexate in Refractory Crohnʼs Disease 1999 ·Inflammatory Bowel Diseases ·Lieven Vandeputte, Geert D’Haens, Filip Baert, Paul Rutgeerts	47
17	Endoscopic and histological healing with infliximab anti–tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial breakdown → 1999 ·Gastroenterology ·Geert D’Haens, Sander van Deventer, (unknown), Douglas M. Chalmers, (unknown), Filip Baert, (unknown), T Schaible, Karel Geboes, Paul Rutgeerts	585
18	Lymphocytic colitis: a distinct clinical entity? A clinicopathological confrontation of lymphocytic and collagenous colitis 1999 ·Gut ·Filip Baert, Karel Wouters, Geert D’Haens, P Hoang, Serge Naegels, F D’Heygere, J Holvoet, E Louis, Martine Devos, Karel Geboes	156
19	Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum breakdown → 1998 ·Gastroenterology ·Geert D’Haens, Karel Geboes, Marc Peeters, Filip Baert, Freddy Penninckx, P. Rutgeerts	668
20	Osteoblast function is suppressed by oral methylprednisolone but not by budesonide CIR in active ileocolonic Crohn's disease 1996 ·Gastroenterology ·G D’Haens, Alain Verstraete, Filip Baert, Marc Peeters, Roger Bouillon, Paul Rutgeerts	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact